These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 25196850

  • 1. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM, Shi Y, Quan J.
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [Abstract] [Full Text] [Related]

  • 2. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
    Richter S, Neundorf I, Loebner K, Gräber M, Berg T, Bergmann R, Steinbach J, Pietzsch J, Wuest F.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4686-9. PubMed ID: 21778054
    [Abstract] [Full Text] [Related]

  • 3. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y, Zhang J, Li D, Jiang J, Wang Y, Si S.
    Oncotarget; 2017 Jan 03; 8(1):1234-1246. PubMed ID: 27902479
    [Abstract] [Full Text] [Related]

  • 4. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB, Woo SU, Yim H.
    J Cell Physiol; 2015 Dec 03; 230(12):3057-67. PubMed ID: 25975351
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chem Biol; 2008 May 03; 15(5):459-66. PubMed ID: 18482698
    [Abstract] [Full Text] [Related]

  • 6. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE, Kim TS, Kim BY, Lee KS.
    Cell Cycle; 2015 May 03; 14(22):3624-34. PubMed ID: 26513691
    [Abstract] [Full Text] [Related]

  • 7. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
    Qin T, Chen F, Zhuo X, Guo X, Yun T, Liu Y, Zhang C, Lai L.
    J Med Chem; 2016 Aug 11; 59(15):7089-96. PubMed ID: 27425654
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
    Lin TY, Min HP, Jiang C, Niu MM, Yan F, Xu LL, Di B.
    Bioorg Med Chem; 2018 Jul 23; 26(12):3429-3437. PubMed ID: 29807699
    [Abstract] [Full Text] [Related]

  • 9. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
    Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK.
    J Med Chem; 2015 Jan 08; 58(1):294-304. PubMed ID: 25347203
    [Abstract] [Full Text] [Related]

  • 10. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
    Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X.
    Acta Pharmacol Sin; 2009 Oct 08; 30(10):1443-53. PubMed ID: 19801998
    [Abstract] [Full Text] [Related]

  • 11. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
    Berg A, Berg T.
    Chembiochem; 2016 Apr 15; 17(8):650-6. PubMed ID: 26662918
    [Abstract] [Full Text] [Related]

  • 12. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1.
    Kim SM, Chae MK, Lee C, Yim MS, Bang JK, Ryu EK.
    Amino Acids; 2014 Nov 15; 46(11):2595-603. PubMed ID: 25151148
    [Abstract] [Full Text] [Related]

  • 13. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
    Raab M, Sanhaji M, Pietsch L, Béquignon I, Herbrand AK, Süß E, Gande SL, Caspar B, Kudlinzki D, Saxena K, Sreeramulu S, Schwalbe H, Strebhardt K, Biondi RM.
    ACS Chem Biol; 2018 Aug 17; 13(8):1921-1931. PubMed ID: 29927572
    [Abstract] [Full Text] [Related]

  • 14. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug 17; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 15. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
    Sun J, Liu HY, Xu RF, Zhu HL.
    Bioorg Med Chem; 2017 Dec 15; 25(24):6581-6588. PubMed ID: 29100732
    [Abstract] [Full Text] [Related]

  • 16. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D, Ramamoorthy G, Varghese J, Nurmemmedov E, McInnes C, Wyatt MD.
    J Med Chem; 2021 Jul 22; 64(14):9916-9925. PubMed ID: 34210138
    [Abstract] [Full Text] [Related]

  • 17. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A, Knappe D, Reindl W, Hoffmann R, Berg T.
    Chembiochem; 2016 Apr 15; 17(8):759-67. PubMed ID: 26634982
    [Abstract] [Full Text] [Related]

  • 18. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chembiochem; 2009 May 04; 10(7):1145-8. PubMed ID: 19350612
    [Abstract] [Full Text] [Related]

  • 19. Vanillin-derived antiproliferative compounds influence Plk1 activity.
    Carrasco-Gomez R, Keppner-Witter S, Hieke M, Lange L, Schneider G, Schubert-Zsilavecz M, Proschak E, Spänkuch B.
    Bioorg Med Chem Lett; 2014 Nov 01; 24(21):5063-9. PubMed ID: 25304894
    [Abstract] [Full Text] [Related]

  • 20. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN, Baxter M, Chapagai D, Stafford JM, Nurmemmedov E, Altomare D, Wyatt MD, McInnes C.
    Eur J Med Chem; 2022 Jan 05; 227():113926. PubMed ID: 34735919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.